On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > REGULATORY
REGULATORY
- In Fight against AMR, Japan Set to Forge Prefectural Networks to Push Proper Antibiotic Use
September 5, 2019
- Senior Bureaucrat Chided for Leaking Draft Clinical Research Bill
September 4, 2019
- Japan, Vietnam Regulators to Hold 1st Joint Symposium Next Month
September 4, 2019
- Japan Drug Production Up 2.8% to 6.9 Trillion Yen in 2018: MHLW
September 2, 2019
- MHLW’s Health Policy Bureau Requests Increased Budget for Core Hospitals, Centers for Pediatric and Rare Diseases
September 2, 2019
- MEXT Requests 103.4 Billion Yen to Fuel Healthcare R&D in FY2020
September 2, 2019
- METI Seeks 5.1 Billion Yen in FY2020 to Develop Technology Platforms for Cell and Gene Therapies
September 2, 2019
- Astellas’ “Post-Nesp” Renal Anemia Drug Now in Line for September Approval, 1st Forteo Biosimilar Too
August 30, 2019
- MHLW Panel Puts a Hold on Possible World’s 1st OK for Ono’s Cancer Cachexia Drug
August 30, 2019
- Ultomiris Caught by CEA Rule despite Intractable Disease Indication: Chuikyo
August 29, 2019
- Tagrisso Gets 15% Re-Pricing, but Other EGFR Drugs Spared: Chuikyo
August 29, 2019
- MHLW Seeks Record 32.6 Trillion Yen Budget for FY2020
August 28, 2019
- Rozlytrek, Onpattro and Many More to Join NHI Price List on Sept. 4
August 28, 2019
- Gene Therapy Collategene Gets 600,000 Yen Price Tag, Peak Sales Put at 1.2 Billion Yen
August 28, 2019
- Public Knowledge-Based Filing OK’ed for Busulfex Use in Lymphoma HSCT
August 27, 2019
- Evenity under PMDA Risk Review
August 27, 2019
- Tagrisso to Face 15% Price Cut in November Because It Sold Too Well
August 27, 2019
- Japan Eyes 1st Revision in 15 Years for Cancer Drug Development Guidelines to Deal with Rare Subtypes, Tumor-Agnostic Indications
August 27, 2019
- AbbVie’s Venetoclax Now in Line for September OK; Tecentriq’s Breast Cancer Use, 2nd Biosimilars and More
August 26, 2019
- MHLW to Seek Budgets to Forge “Drugs for Specific Use” System for FY2020
August 23, 2019
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…